Chiltern, the contract research organization that acquired Cary-based Ockham in July, has expanded its presence in the Asia-Pacific region by acquiring a small Singapore company.
With the acquisition of Pacific Clinical Research, announced Monday, Chiltern now has 85 employees in the region – roughly half of whom came with the Pacific Clinical acquisition. The purchase price wasn’t disclosed.
The deal “puts us in a more competitive position as a truly global service provider,” Nicholas Spittal, senior director of global clinical development, said in an e-mail message.
Chiltern has 2,200 employees in 45 countries. Contract research organizations such as Chiltern help pharmaceutical and biotechnology companies conduct extensive tests on experimental medicines required by regulators before they will consider approving a drug.
One of Pacific Clinical’s strengths is working with experimental cancer drugs, which also was a specialty of Ockham. Ockham had about 150 employees in North Carolina and 500 workers overall when it was purchased by Chiltern two months ago.